The Janssen Pharmaceutical, a Johnson & Johnson company, reported the U.S. Food and Drug Administration (FDA) granted its JNJ-6372 Breakthrough Therapy Designation. The drug is being developed for metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations where the disease has progressed while the patient is on or after receiving platinum-based chemotherapy.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,